bristol-myers squibb news - Search News

Bristol Myers Squibb, FDA

Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic drugs.

Seeking Alpha · 2d

Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress

Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of Schizophrenia. See why BMY stock is a Buy.

CNBC on MSN · 2d

Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug

CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.

3d

Bristol Myers Squibb Vs. AbbVie Stock

Given its better valuation, we believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its peer – ...

2don MSN

These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More

Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...

A new kind of drug for schizophrenia promises fewer side effects

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

2d

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential

Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results